Gastroenterology
Volume 129, Issue 3 , Pages 1114-1116 , September 2005

C-Reactive Protein: Anti-Placebo or Predictor of Response

  • James D. Lewis

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: James D. Lewis, MD, MSCE, 720 Blockley Hall, 423 Guardian Drive, Philadelphia, Pennsylvania 19104; fax: (215) 573-5325.

References 

  1. Su C , Lichtenstein GR , Krok K , Brensinger CM , Lewis JD . A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease . Gastroenterology . 2004;126:1257–1269
  2. Will M , Nikolaus S , Freitag S , Arpe N , Krawczak M , Schreiber S . Placebo response in the therapy of Crohn’s disease (a comprehensive analysis of primary data from 733 patients from 13 randomized controlled trials) . Gastroenterology . 2005;128(Suppl 2):A-48
  3. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kann MA, Boivin M, et al. A randomized, placebo-controlled trial of Certolizumab pegol (CDP870) for treatment of Crohn’s disease . Gastroenterology . 2005;129:807–818
  4. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn’s disease (a randomised, double blind, placebo controlled trial) . Gut . 2004;53:1485–1493
  5. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab Pan-European Study G. Natalizumab for active Crohn’s disease . N Engl J Med . 2003;348:24–32
  6. Rutgeerts P , Colombel JF , Enns J . Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn’s disease . Gut . 2003;52(Suppl):A239
  7. Camilleri M , Northcutt AR , Kong S , Dukes GE , McSorley D , Mangel AW . Efficacy and safety of alosetron in women with irritable bowel syndrome (a randomised, placebo-controlled trial) . Lancet . 2000;355:1035–1040
  8. Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome . Arch Intern Med . 2001;161:1733–1740
  9. Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis . Eur J Clin Invest . 1982;12:351–359
  10. Chambers RE , Stross P , Barry RE , Whicher JT . Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease . Eur J Clin Invest . 1987;17:460–467
  11. Solem CA , Loftus EV , Tremaine WJ , Harmsen S , Zinsmeister AR , Sandborn WJ . Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease . Gastroenterology . 2004;126(Suppl 2):A-477
  12. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, et al. A positive response to infliximab in Crohn disease (association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism) . Scand J Gastroenterol . 2002;37:818–824
  13. Tillet W , Francis T . Serological reactions in pneumonia with a non-protein somatic fraction of the Pneumococcus . J Exp Med . 1930;52:561–571

PII: S0016-5085(05)01549-0

doi: 10.1053/j.gastro.2005.07.041

Gastroenterology
Volume 129, Issue 3 , Pages 1114-1116 , September 2005

Article Tools